AstraZeneca Rejects Pfizer “Final” Offer; Doubts Rise Over Eventual Deal
This article was originally published in The Pink Sheet Daily
AstraZeneca received and rejected Pfizer’s latest, higher bid over the weekend, casting real doubt over the US group’s plan for a merger to create the world's biggest drugmaker – but analysts say Pfizer, which says it won’t turn hostile, could raise its offer one last time.
You may also be interested in...
A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.
Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.
Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.